Skip to main content
Top
Published in: International Urology and Nephrology 3/2010

01-09-2010 | Nephrology – Case Report

Primary hyperparathyroidism associated with hypocalcemia in a patient presenting with kidney disease

Authors: Sylvie Dusilova Sulkova, Jiri Horacek, Pavel Zivny, Pavla Rehorkova, Miloslav Podhola, Mirko Kadlec, Ctibor Povysil

Published in: International Urology and Nephrology | Issue 3/2010

Login to get access

Abstract

Elevated serum parathyroid hormone (PTH) level together with hypocalcemia in chronic kidney disease usually suggests secondary hyperparathyroidism. However, primary hyperparathyroidism should also be considered, especially if concomitant vitamin D deficiency is suspected. We report a case of parathyroid adenoma associated with hypocalcemia and metabolic bone disease in a patient presenting with kidney disorder. The patient was successfully treated by parathyroidectomy that was preceded and followed by intensive calcium and vitamin D supplementation.
Literature
2.
go back to reference Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348–5352CrossRefPubMed Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348–5352CrossRefPubMed
3.
go back to reference Lowe H, McMahon DJ, Rubin MR et al (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrin Metab 92:3001–3005CrossRef Lowe H, McMahon DJ, Rubin MR et al (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrin Metab 92:3001–3005CrossRef
5.
go back to reference Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of biphosphonates in the treatment of osteoporosis. Am J Med 122(2A):S22–S32CrossRefPubMed Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of biphosphonates in the treatment of osteoporosis. Am J Med 122(2A):S22–S32CrossRefPubMed
6.
go back to reference Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(Suppl. 1):6222s–6230sCrossRefPubMed Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(Suppl. 1):6222s–6230sCrossRefPubMed
7.
go back to reference Toussaint ND, Elder GJ, Kerr PG (2009) Bisphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233CrossRefPubMed Toussaint ND, Elder GJ, Kerr PG (2009) Bisphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233CrossRefPubMed
8.
go back to reference Rix M, Andreassen H, Eskildsen P et al (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093CrossRefPubMed Rix M, Andreassen H, Eskildsen P et al (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093CrossRefPubMed
9.
go back to reference Reichel H, Roth HJ, Schmidt-Gayk H (2004) Evolution of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract 98:c112–c118CrossRefPubMed Reichel H, Roth HJ, Schmidt-Gayk H (2004) Evolution of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract 98:c112–c118CrossRefPubMed
10.
go back to reference Cavalier E, Delanaye P, Collette J et al (2006) Evaluation of different bone markers in hemodialyzed patients. Clinica Chimica Acta 37:107–111CrossRef Cavalier E, Delanaye P, Collette J et al (2006) Evaluation of different bone markers in hemodialyzed patients. Clinica Chimica Acta 37:107–111CrossRef
11.
go back to reference Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among hemodialysis patients. Kidney Int 72:1004–1113CrossRefPubMed Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among hemodialysis patients. Kidney Int 72:1004–1113CrossRefPubMed
12.
go back to reference Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) Vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38:323–329CrossRefPubMed Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) Vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38:323–329CrossRefPubMed
13.
go back to reference Bouchard J, Quimet D, Vallée M et al (2009) Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporoic populations. Int Urol Nephrol 41:983–988CrossRefPubMed Bouchard J, Quimet D, Vallée M et al (2009) Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporoic populations. Int Urol Nephrol 41:983–988CrossRefPubMed
Metadata
Title
Primary hyperparathyroidism associated with hypocalcemia in a patient presenting with kidney disease
Authors
Sylvie Dusilova Sulkova
Jiri Horacek
Pavel Zivny
Pavla Rehorkova
Miloslav Podhola
Mirko Kadlec
Ctibor Povysil
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9743-6

Other articles of this Issue 3/2010

International Urology and Nephrology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.